

Received SEC

OCT 18 2016

William Slattery, CFA  
Vice President  
Listing Qualifications

Washington, DC 20549



CERTINAS  
001-37923

Electronic Mail Only

October 18, 2016

Mr. Jeffrey Thomas  
Chief, IT Services  
Division of Corporation Finance  
U.S. Securities and Exchange Commission  
100 F Street, N.E.  
Washington, D.C. 20549



16004890

Dear Mr. Thomas:

This is to certify that on October 18th, 2016 The Nasdaq Stock Market (the "Exchange") received from CRISPR Therapeutics AG (the "Registrant") a copy of the Registrant's application on Form 8-A 12(b) for the registration of the following security:

Common Shares, CHF 0.03 nominal value per share

We further certify that the security described above has been approved by the Exchange for listing and registration upon official notice of issuance.

We understand that the Registrant is seeking effectiveness of the Form 8-A 12(b) concurrently with effectiveness of its 1933 Act Registration Statement, and we hereby join in such request.

Sincerely,

*William Slattery*